Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
976 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06880029 | Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy(CIRCADIAN) | recruiting | Phase 1 / Phase 2 | 20 | Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.OTHER_GOV | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02492711 | Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer(SOPHIA) | completed | Phase 3 | 624 | MacroGenicsINDUSTRY | 18 |
| Mar 17, 2025 |
| clinicaltrials |
| NCT04960735 | Implementation, Effectiveness and Impact of a Value Based Intervention for Patients with Breast or Lung Cancer(VOICE) | completed | N/A | 1,007 | Biosistemak Institute for Health Systems ResearchOTHER | 5 | Mar 10, 2025 | clinicaltrials |
| NCT01160211 | A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | completed | Phase 3 | 369 | Novartis PharmaceuticalsINDUSTRY | 29 | Mar 7, 2025 | clinicaltrials |
| NCT01865110 | R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL | completed | Phase 3 | 623 | The Lymphoma Academic Research OrganisationOTHER | 7 | Mar 5, 2025 | clinicaltrials |
| NCT06316882 | Gastric Cancer Endoscopic Screening in an Intermediate-risk Country - ROGCAS, a Dual-centre Pilot Program(ROGCAS) | completed | — | 349 | Unidade Local De Saúde Do Norte AlentejanoOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06703632 | Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection(MS-Prevecol) | recruiting | N/A | 4,538 | ADVANCED MARKER DISCOVERY S.L.INDUSTRY | 2 | Feb 27, 2025 | clinicaltrials |
| NCT06848270 | Effectiveness of Early Intervention in Palliative Care for Acute Myeloid Leukemia Patients Comparing to Standard of Care | not yet recruiting | N/A | 50 | Universidade do PortoOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT02807636 | Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma(IMvigor130) | completed | Phase 3 | 1,213 | Hoffmann-La RocheINDUSTRY | 35 | Feb 24, 2025 | clinicaltrials |
| NCT03659136 | The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread | completed | Phase 2 | 103 | Boehringer IngelheimINDUSTRY | 11 | Feb 24, 2025 | clinicaltrials |
| NCT03400150 | BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007 | completed | N/A | 222 | BioProtectINDUSTRY | 6 | Feb 18, 2025 | clinicaltrials |
| NCT01828112 | LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib | completed | Phase 3 | 231 | Novartis PharmaceuticalsINDUSTRY | 20 | Feb 7, 2025 | clinicaltrials |
| NCT01715285 | A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) | completed | Phase 3 | 1,209 | Janssen Research & Development, LLCINDUSTRY | 33 | Feb 4, 2025 | clinicaltrials |
| NCT03796858 | A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy(COSMOS) | completed | Phase 3 | 285 | Janssen Pharmaceutica N.V., BelgiumINDUSTRY | 14 | Feb 3, 2025 | clinicaltrials |
| NCT01644669 | Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System® | active not recruiting | N/A | 1,200 | Xoft, Inc.INDUSTRY | 3 | Jan 31, 2025 | clinicaltrials |
| NCT02576574 | Avelumab in First-line NSCLC (JAVELIN Lung 100) | completed | Phase 3 | 1,214 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 42 | Jan 31, 2025 | clinicaltrials |
| NCT06802627 | Prehabilitation for Lung Cancer Patients Undergoing Lung Resection(Fit4LungNeo) | not yet recruiting | N/A | 200 | Universidade do PortoOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT03366272 | Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients(NIVEAU) | completed | Phase 2 / Phase 3 | 348 | Universität des SaarlandesOTHER | 8 | Jan 28, 2025 | clinicaltrials |
| NCT06529302 | The OPBC-07/microNAC Study | active not recruiting | — | 2,000 | University Hospital, Basel, SwitzerlandOTHER | 30 | Jan 24, 2025 | clinicaltrials |
| NCT06782698 | Home-Based Exercise Program During Neoadjuvant Treatment to Improve Fatigue and Quality of Life in Early HER2-Positive and Triple-Negative Breast Cancer Patients(HoPEx-Breast) | active not recruiting | N/A | 50 | Centro Hospitalar Universitário de Santo AntónioOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT02990338 | Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients(ICARIA-MM) | completed | Phase 3 | 307 | SanofiINDUSTRY | 24 | Jan 17, 2025 | clinicaltrials |
| NCT04109066 | Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer(CheckMate 7FL) | completed | Phase 3 | 521 | Bristol-Myers SquibbINDUSTRY | 32 | Jan 8, 2025 | clinicaltrials |
| NCT05205161 | A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma | terminated | Phase 1 | 7 | AstraZenecaINDUSTRY | 7 | Jan 7, 2025 | clinicaltrials |
| NCT00418886 | Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients(ZEAL) | completed | Phase 3 | 698 | Genzyme, a Sanofi CompanyINDUSTRY | 21 | Dec 31, 2024 | clinicaltrials |
| NCT03673306 | Safety of Pregnancy in BRCA Mutated Breast Cancer Patients | completed | — | 4,732 | Jules Bordet InstituteOTHER | 26 | Dec 13, 2024 | clinicaltrials |
| NCT02626455 | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)(CHRONOS-4) | terminated | Phase 3 | 551 | BayerINDUSTRY | 35 | Dec 11, 2024 | clinicaltrials |
| NCT02588261 | A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations(SOLAR) | terminated | Phase 3 | 530 | Astellas Pharma Global Development, Inc.INDUSTRY | 23 | Dec 10, 2024 | clinicaltrials |
| NCT02216786 | A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer(MANTA) | completed | Phase 2 | 333 | Queen Mary University of LondonOTHER | 9 | Dec 2, 2024 | clinicaltrials |
| NCT02927262 | A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission | completed | Phase 2 | 98 | Astellas Pharma Global Development, Inc.INDUSTRY | 21 | Nov 26, 2024 | clinicaltrials |
| NCT03944798 | Surveillance AFter Extremity Tumor surgerY(SAFETY) | active not recruiting | N/A | 310 | McMaster UniversityOTHER | 14 | Nov 22, 2024 | clinicaltrials |
| NCT02181413 | A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant | completed | Phase 3 | 656 | TakedaINDUSTRY | 33 | Nov 19, 2024 | clinicaltrials |
| NCT01318642 | Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas | terminated | Phase 2 | 10 | NantBioScience, Inc.INDUSTRY | 13 | Nov 8, 2024 | clinicaltrials |
| NCT03565445 | A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors | completed | Phase 1 | 190 | Astellas Pharma Global Development, Inc.INDUSTRY | 9 | Nov 1, 2024 | clinicaltrials |
| NCT03191786 | A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy(IPSOS) | completed | Phase 3 | 453 | Hoffmann-La RocheINDUSTRY | 24 | Oct 23, 2024 | clinicaltrials |
| NCT02495974 | European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)(PREMISE) | completed | — | 1,763 | Astellas Pharma Europe Ltd.INDUSTRY | 16 | Oct 21, 2024 | clinicaltrials |
| NCT03240523 | A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 5) | terminated | Phase 3 | 766 | BayerINDUSTRY | 23 | Oct 18, 2024 | clinicaltrials |
| NCT04134936 | Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL | completed | Phase 1 | 66 | MorphoSys AGINDUSTRY | 9 | Oct 16, 2024 | clinicaltrials |
| NCT03447769 | Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A(Canopy-A) | terminated | Phase 3 | 1,382 | Novartis PharmaceuticalsINDUSTRY | 41 | Oct 9, 2024 | clinicaltrials |
| NCT03452137 | A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck(IMvoke010) | terminated | Phase 3 | 406 | Hoffmann-La RocheINDUSTRY | 23 | Oct 9, 2024 | clinicaltrials |
| NCT04898855 | Internet-delivered Cognitive-Behavioral Intervention for Insomniac Cancer Survivors | completed | N/A | 154 | University of CoimbraOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT03822351 | Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC(COAST) | completed | Phase 2 | 189 | MedImmune LLCINDUSTRY | 9 | Oct 8, 2024 | clinicaltrials |
| NCT01794793 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | completed | Phase 4 | 337 | RECORDATI GROUPINDUSTRY | 28 | Oct 1, 2024 | clinicaltrials |
| NCT04521621 | A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | terminated | Phase 1 / Phase 2 | 76 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Oct 1, 2024 | clinicaltrials |
| NCT04753658 | Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib | terminated | — | 15 | PfizerINDUSTRY | 6 | Sep 23, 2024 | clinicaltrials |
| NCT01285557 | Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial(DIGEST) | terminated | Phase 3 | 361 | Taiho Oncology, Inc.INDUSTRY | 20 | Sep 19, 2024 | clinicaltrials |
| NCT02500043 | Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer | completed | Phase 3 | 507 | Taiho Oncology, Inc.INDUSTRY | 18 | Sep 3, 2024 | clinicaltrials |
| NCT05642897 | Mind Programme for Women With Breast Cancer(MIND) | unknown | N/A | 150 | University of CoimbraOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT03402841 | Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients(OPINION) | completed | Phase 3 | 279 | AstraZenecaINDUSTRY | 19 | Aug 21, 2024 | clinicaltrials |
| NCT05947903 | Validation of the European Oncology Quality of Life Toolkit | unknown | — | 4,000 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 32 | Aug 20, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials